TBIC: Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children

• Sponsor: Vanderbilt University (Other)
• Overall Status: Completed
• CT.gov ID: NCT02712996
• Collaborator: Shire (Industry)
• Enrollment: 20
• Location: 1
• Arms: 2
• Actual Duration (Months): 28.7
• Patients Per Site Per Month: 0.7

Study Details

Study Description

Brief Summary

The purpose of this research study is to evaluate whether Vyvanse, a psychostimulant, can help children ages 6-16 with attention deficits due to traumatic brain injury (TBI). Vyvanse is currently approved for the treatment of Attention-Deficit/Hyperactivity (ADHD). The exact effects this drug may have on adults with attention deficits caused by TBI have been investigated prior. The exact effects this drug may have on children with attention deficits caused by TBI are not known, but the investigators expect that Vyvanse will be of some help in treating this population as well.

Condition or Disease	Intervention/Treatment	Phase
Traumatic Brain Injury; Attention Deficit Disorder	Drug: Lisdexamfetamine; Drug: Placebo	Phase 4

Detailed Description

Symptoms of inattentiveness, impulsivity, and poor persistence have been observed in children following traumatic brain injury (TBI). These often are among the most prominent symptoms manifested and may contribute to interference in a variety of other functional domains. Although there has been some use of psychostimulant medication to treat TBI-acquired attention deficits, it remains a relatively uncommon clinical practice. This study, by highlighting mechanisms of action, could serve to promote the appropriate use of this type of treatment for the patients.

Study Design

• Study Type: Interventional
• Actual Enrollment: 20 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: Treatment Outcomes With Lisdexamfetamine Dimesylate (Vyvanse) in Children With Traumatic Brain Injury-Related Attention Deficits
• Actual Study Start Date: Feb 6, 2017
• Actual Primary Completion Date: Jul 1, 2019
• Actual Study Completion Date: Jul 1, 2019

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Vyvanse Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.	Drug: Lisdexamfetamine; Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.; Other Names: Vyvanse
Placebo Comparator: Placebo Placebo capsule, 20-70 mg, each morning for 6 weeks.	Drug: Placebo; Placebo capsule, 20-70 mg, each morning for 6 weeks.

Outcome Measures

Primary Outcome Measures

1. Assessing Severity of Symptoms Associated With Attention-deficit/Hyperactivity Disorder (ADHD) in Children When Using Vyvanse Versus Placebo by Administering the Conners-3 Parent Form [12 weeks]

   The Conners-3 Parent Form is used to obtain the parent's observations about behavior in their child aged 6 to 18 years old. Parents rate the child's behavior on 45 items as not true at all (0) to very much true (3). The lowest scale score is 0 (better behavior) and the highest is 135 (worse behavior). The Conners 3-P includes content Scales of Inattention, Hyperactivity/Impulsivity, Learning Problems, Executive Functioning, Aggression, and Peer/Family Relations. Inattention scale was reported as the Primary Outcome. All scores were converted to z-scores (M=0, SD=+/-1).

2. Assessing Executive Functioning in Children When Using Vyvanse Versus Placebo by Administering the Behavior Rating Inventory of Executive Function (BRIEF) - PARENT [12 weeks]

   The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). GEC was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).

3. Assessing Inattentiveness in Children Using Vyvanse Versus Placebo by Measuring Omissions on the Conners Continuous Performance Task (CPT-II). [12 weeks]

   Conner's Continuous Performance Task (CPT-II) measures sustained attention and response inhibition. During the CPT-II, letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). Omission errors represented the number of times a participant fails to respond to target letters (all other than 'X'). Raw scores were converted to z-scores (M=0, SD=+/-1). Higher scores indicate greater inattentiveness.

4. Assessing Physical Symptoms in Children Using Vyvanse Versus Placebo by Measuring Anxiety on the Revised Child Manifest Anxiety Scale (RCMAS) [12 weeks]

   RCMAS is a self-report, 37-item questionnaire in which children agree (yes = 1) or disagree (no =0) to statements about themselves. A Total Anxiety score is computed based on 28 items, which are divided into 3 anxiety subscales: physiological anxiety (10 items), worry/oversensitivity (11 items), and social concerns/concentration (7 items). The remaining nine items on the RCMAS constitute the Lie (social desirability) subscale. The lowest scale score is 0 and the highest is 37. Raw scores were converted to z-scores (M=0, SD=+/-1). Because scores are derived from affirmative responses, a high score indicates a high level of anxiety or lie on that subscale.

5. Assessing Total Symptoms in Children Using Vyvanse Versus Placebo by Measuring Anxiety on the Revised Child Manifest Anxiety Scale (RCMAS) [12 weeks]

   RCMAS is a self-report, 37-item questionnaire in which children agree (yes = 1) or disagree (no =0) to statements about themselves. A Total Anxiety score is computed based on 28 items, which are divided into 3 anxiety subscales: physiological anxiety (10 items), worry/oversensitivity (11 items), and social concerns/concentration (7 items). The remaining nine items on the RCMAS constitute the Lie (social desirability) subscale. The lowest scale score is 0 and the highest is 37. Raw scores were converted to z-scores (M=0, SD=+/-1). Because scores are derived from affirmative responses, a high score indicates a high level of anxiety or lie on that subscale.

6. Assessing Attention Problems in Children Using Vyvanse Versus Placebo by Measuring Symptoms on the Child Behavior Checklist (CBCL) [12 weeks]

   The Child Behavior Checklist (CBCL) is a widely used caregiver report form identifying problem behavior in children. The patient is rated on 113 items scored on a 3-point Likert scale (0=not true; 1=somewhat/sometimes true; 2=very true/often true). CBCL consists of eight empirically-based syndrome subscales. The range of subscale scores (summed) are: Aggressive Behavior (0-36), Anxious/Depressed (0-26), Attention Problems (0-20), Rule-Breaking Behavior (0-34), Somatic Complaints (0-22), Social Problems (0-22), Thought Problems (0-30), and Withdrawn/Depressed (0-16). Raw scores were converted to z-scores (M=0, SD=+/-1). Higher scores indicate more severe symptoms.

7. Assessing Anxiety-Depression Problems in Children Using Vyvanse Versus Placebo by Measuring Symptoms on the Child Behavior Checklist (CBCL) [12 weeks]

   The Child Behavior Checklist (CBCL) is a widely used caregiver report form identifying problem behavior in children. The patient is rated on 113 items scored on a 3-point Likert scale (0=not true; 1=somewhat/sometimes true; 2=very true/often true). CBCL consists of eight empirically-based syndrome subscales. The range of subscale scores (summed) are: Aggressive Behavior (0-36), Anxious/Depressed (0-26), Attention Problems (0-20), Rule-Breaking Behavior (0-34), Somatic Complaints (0-22), Social Problems (0-22), Thought Problems (0-30), and Withdrawn/Depressed (0-16). Raw scores were converted to z-scores (M=0, SD=+/-1). Higher scores indicate more severe symptoms.

8. Assessing Inhibitory Control in Children When Using Vyvanse Versus Placebo Utilizing the Inhibit Subscale on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS [12 weeks]

   The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Inhibit was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).

9. Assessing Ability to Tolerate Change in Children When Using Vyvanse Versus Placebo by Utilizing the Shift Subscale on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS [12 weeks]

   The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Shift was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).

10. Assessing Ability to Begin Tasks in Children When Using Vyvanse Versus Placebo by Utilizing the Initiate Subscale on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS [12 weeks]

    The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Initiate was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).

11. Assessing Representational Memory in Children When Using Vyvanse Versus Placebo by Utilizing the Working Memory Subscale on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS [12 weeks]

    The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Working Memory was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).

12. Assessing Task-oriented Monitoring in Children When Using Vyvanse Versus Placebo by Utilizing the Monitor Subscale on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS [12 weeks]

    The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Monitor was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).

13. Assessing Behavior Regulation in Children When Using Vyvanse Versus Placebo by Measuring the Behavior Regulation Index (BRI) on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS [12 weeks]

    The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Behavior Regulation was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).

14. Assessing Cognitive Regulation in Children When Using Vyvanse Versus Placebo by Measuring the Cognitive Regulation Index (CRI) on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS [12 weeks]

    The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Cognitive Regulation was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).

15. Assessing Emotion Regulation in Children When Using Vyvanse Versus Placebo by Measuring the Emotion Regulation Index (ERI) on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS [12 weeks]

    The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Emotion regulation was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).

16. Assessing Hyperactivity in Children When Using Vyvanse Versus Placebo by Administering the Conners-3 Parent Form [12 weeks]

    The Conners-3 Parent Form is used to obtain the parent's observations about behavior in their child aged 6 to 18 years old. Parents rate the child's behavior on 45 items as not true at all (0) to very much true (3). The lowest scale score is 0 (better behavior) and the highest is 135 (worse behavior). The Conners 3-P includes content Scales of Inattention, Hyperactivity/Impulsivity, Learning Problems, Executive Functioning, Aggression, and Peer/Family Relations. Hyperactivity was reported as the Primary Outcome. All scores were converted to z-scores (M=0, SD=+/-1).

17. Assessing Executive Functioning in Children When Using Vyvanse Versus Placebo by Administering the Conners-3 Parent Form [12 weeks]

    The Conners-3 Parent Form is used to obtain the parent's observations about behavior in their child aged 6 to 18 years old. Parents rate the child's behavior on 45 items as not true at all (0) to very much true (3). The lowest scale score is 0 (better behavior) and the highest is 135 (worse behavior). The Conners 3-P includes content Scales of Inattention, Hyperactivity/Impulsivity, Learning Problems, Executive Functioning, Aggression, and Peer/Family Relations. Executive Functioning was reported as the Primary Outcome. All scores were converted to z-scores (M=0, SD=+/-1).Higher T-scores

Secondary Outcome Measures

1. Assessing Executive Functioning in Children When Using Vyvanse Versus Placebo by Administering the Behavior Rating Inventory of Executive Function (BRIEF) - CHILD SELF REPORT [12 weeks]

   The BRIEF Self-Report Version assesses an adolescent's (ages 11-18) view of his or her cognitive, emotional, and behavioral functions. It is a validated 55-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Inhibit, Shift, Emotional Control, Monitor, Working Memory, Plan/Organize, Organization of Materials, and Task Completion). For each item, the child rates whether they engage in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 55 (better performance) and the highest is 165 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). GEC was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).

2. Assessing Working Memory and Concentration in Children Using Vyvanse Versus Placebo by Measuring Performance on the Digit Span Subtest of the Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V) [12 weeks]

   Digit Span repeats strings of digits of increasing length said by the examiner. Participants were asked to repeat the digits in the same sequence, either forwards or backwards. Every item on Digit Span consists of two trials. One point was awarded if the participant passed only 1 trial of a sequence length. Zero points were given if the participant failed both trials. It measures working memory and concentration with a range of scaled scores from 0-19. Raw scores were converted to z-scores (M=0, SD=+/-1). Higher scores indicate better recall and attention.

3. Assessing Sustained Attention and Response Inhibition in Children Using Vyvanse Versus Placebo by Measuring Reaction Time (RT) Standard Error (SE) on the Conners Continuous Performance Task (CPT-II). [12 weeks]

   Conner's Continuous Performance Task (CPT-II) measure sustained attention and response inhibition. During the CPT-II, letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). Raw scores were converted to z-scores (M=0, SD=+/-1). Hit Reaction Time (RT) Standard Error (SE) measures response speed consistency. The higher the Overall Standard Error, the greater the inconsistency in the response speed, indicating a greater amount of inattention.

4. Assessing Sustained Attention and Response Inhibition in Children Using Vyvanse Versus Placebo by Measuring RT Inter-Stimulus Interval (ISI) on the Conners Continuous Performance Task (CPT-II). [12 weeks]

   Conner's Continuous Performance Task (CPT-II) measure sustained attention and response inhibition. During the CPT-II, letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). CPT-II Hit Reaction Time (RT) Inter-Stimulus Interval (ISI) Change assesses the ability to adapt to changing inter-stimulus intervals. Inter-stimulus intervals refers to the amount of time between presentation of stimuli. High t-scores indicate that RT increased as the ISI increased; negative values indicate that RT decreased as the ISI increased. Less Hit RT ISI Change indicates less variability in RT depending on the speed of presentation.

5. Assessing Sustained Attention and Response Inhibition in Children Using Vyvanse Versus Placebo by Measuring Hit Reaction Time (RT) Block Change on the Conners Continuous Performance Task (CPT-II). [12 weeks]

   Conner's Continuous Performance Task (CPT-II) measures sustained attention and response inhibition. During the CPT-II, letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). Raw scores were converted to z-scores (M=0, SD=+/-1). Overall hit reaction time is the average speed of correct responses for the entire test. Lower values indicate that responses got quicker as the test progressed. High values indicate a substantial slowing in reaction times.

6. Assessing Sustained Attention and Response Inhibition in Children Using Vyvanse Versus Placebo by Measuring Perseverations on the Conners Continuous Performance Task (CPT-II). [12 weeks]

   Conner's Continuous Performance Task (CPT-II) measures sustained attention and response inhibition. During the CPT-II, letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). CPT-II Perseverations represent responses in which reaction time was less than 100 ms; these responses are assumed to be anticipatory, random, or slow/inattentive (i.e., carried over from the previous response) because it is physiologically impossible to respond accurately in so short a time. Raw scores were converted to z-scores (M=0, SD=+/-1) to have them on a uniform metric. Higher scores indicate greater inattentiveness.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 6 Years to 16 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Males and females ages 6 to 16

• Traumatic brain injury rated as mild/moderate/severe (based on Glasgow Coma Scale, estimated posttraumatic amnesia, indications of intracranial injury on CT scan, etc.)

• Sustained 2-36 months earlier

• Considered to be neurologically stable (absence of post-acute symptoms of confusion, disorientation, etc.)

• Persistent (> 2 months) problems with focused or sustained attention

• Problems with attention/concentration rated as among the most prominent cognitive changes

• Accompanying features may include diminished arousal/speed/stamina and/or hyperactivity/impulsivity symptoms.

Exclusion Criteria:

• Cases with primarily penetrating head trauma

• Pre-injury history of diagnosed ADHD

• Pre-injury history of other neurodevelopmental disorders including intellectual disabilities, major communication disorders, autism spectrum disorder

• Unstable or serious psychiatric conditions, such as psychotic symptoms. Concurrent problems with depression, anxiety, or post-traumatic stress disorder may be present but are judged to be stable and not so severe as to require pharmacologic treatment

• Treatment with psychotropic medication(s), including psychostimulant(s) within the last 6 months, but eligible thereafter

• Lifetime history of stimulant abuse or dependence. Other (non-stimulant) substance abuse within the past 6 months.

• Tics or other contraindications for psychostimulant use including cardiovascular disease, uncontrolled hypertension or hyperthyroidism, glaucoma, agitation, use of an monoamine oxidase (MAO) inhibitor within the past six weeks. Pregnancy would also be an exclusion for girls of childbearing age.

• Estimated intelligence quotient (IQ) < 70

• Sensory and/or motor impairment(s) seriously limiting testing options

• Neurological conditions including uncontrolled epilepsy, degenerative disorders, brain tumor, or stroke

• Physical condition affecting arousal, activity level, or stamina including uncontrolled thyroid dysfunction, severe or symptomatic anemia, autoimmune or metabolic disorders, untreated moderate/severe sleep apnea, etc.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Vanderbilt Medical Center	Nashville	Tennessee	United States	37203

Sponsors and Collaborators

• Vanderbilt University
• Shire

Investigators

• Principal Investigator: Michael G Tramontana, Ph.D, Vanderbilt University

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Apr 19, 2018

More Information

Publications

None provided.

• Responsible Party: Michael G. Tramontana, Ph.D., Associate Professor of Psychiatry and Neurology, Vanderbilt University
• ClinicalTrials.gov Identifier: NCT02712996
• Other Study ID Numbers: TBI 56592
• First Posted: Mar 18, 2016
• Last Update Posted: Jul 13, 2020
• Last Verified: Jun 1, 2020

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Keywords provided by Michael G. Tramontana, Ph.D., Associate Professor of Psychiatry and Neurology, Vanderbilt University: Traumatic Brain Injury; Attention Deficit; TBI; Vyvanse
• Additional relevant MeSH terms: Brain Injuries; Brain Injuries, Traumatic; Wounds and Injuries; Attention Deficit Disorder with Hyperactivity; Lisdexamfetamine Dimesylate

Study Results

Participant Flow

Pre-assignment Detail	Of 20 enrolled participants, 3 never began the trial due to scheduling problems or competing demands.

Arm/Group Title	Lisdexamfetamine (Vyvanse) Then Placebo	Placebo Then Vyvanse
Arm/Group Description	Participants first received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks. On day 43 after treatment initiation, each subject was switched to placebo capsule, 20-70 mg, each morning for 6 weeks.	Participants first received Placebo capsule, 20-70 mg, each morning for 6 weeks. On day 43 after treatment initiation, participants received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks
Period Title: First Intervention (Study Days 1-42)
STARTED	8	9
COMPLETED	8	9
NOT COMPLETED	0	0
Period Title: First Intervention (Study Days 1-42)
STARTED	8	9
COMPLETED	8	8
NOT COMPLETED	0	1

Baseline Characteristics

Arm/Group Title	Lisdexamfetamine (Vyvanse) Then Placebo	Placebo Then Lisdexamfetamine (Vyvanse)	Total
Arm/Group Description	Participants first received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks. Then on day 43 after treatment initiation, each subject received Placebo capsule, 20-70 mg, each morning for 6 weeks	Participants first received Placebo capsule, 20-70 mg, each morning for 6 weeks. Then on day 43 after treatment initiation, each subject received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.	Total of all reporting groups
Overall Participants	8	9	17
Age (Count of Participants)
<=18 years	8 100%	9 100%	17 100%
Between 18 and 65 years	0 0%	0 0%	0 0%
>=65 years	0 0%	0 0%	0 0%
Sex: Female, Male (Count of Participants)
Female	4 50%	5 55.6%	9 52.9%
Male	4 50%	4 44.4%	8 47.1%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%	0 0%	0 0%
Not Hispanic or Latino	0 0%	0 0%	0 0%
Unknown or Not Reported	8 100%	9 100%	17 100%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%
Asian	0 0%	0 0%	0 0%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%
Black or African American	0 0%	0 0%	0 0%
White	8 100%	7 77.8%	15 88.2%
More than one race	0 0%	2 22.2%	2 11.8%
Unknown or Not Reported	0 0%	0 0%	0 0%
Region of Enrollment (participants) [Number]
United States	8 100%	9 100%	0 0%

Outcome Measures

1. Primary Outcome

Title	Assessing Severity of Symptoms Associated With Attention-deficit/Hyperactivity Disorder (ADHD) in Children When Using Vyvanse Versus Placebo by Administering the Conners-3 Parent Form
Description	The Conners-3 Parent Form is used to obtain the parent's observations about behavior in their child aged 6 to 18 years old. Parents rate the child's behavior on 45 items as not true at all (0) to very much true (3). The lowest scale score is 0 (better behavior) and the highest is 135 (worse behavior). The Conners 3-P includes content Scales of Inattention, Hyperactivity/Impulsivity, Learning Problems, Executive Functioning, Aggression, and Peer/Family Relations. Inattention scale was reported as the Primary Outcome. All scores were converted to z-scores (M=0, SD=+/-1).
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event.

Arm/Group Title	Lisdexamfetamine (Vyvanse)	Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.	Participants who received Placebo capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	1.00 (1.11)	1.76 (1.47)

2. Primary Outcome

Title	Assessing Executive Functioning in Children When Using Vyvanse Versus Placebo by Administering the Behavior Rating Inventory of Executive Function (BRIEF) - PARENT
Description	The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). GEC was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Lisdexamfetamine (Vyvanse)	Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.	Participants who received Placebo capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	0.51 (0.99)	1.16 (1.33)

3. Primary Outcome

Title	Assessing Inattentiveness in Children Using Vyvanse Versus Placebo by Measuring Omissions on the Conners Continuous Performance Task (CPT-II).
Description	Conner's Continuous Performance Task (CPT-II) measures sustained attention and response inhibition. During the CPT-II, letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). Omission errors represented the number of times a participant fails to respond to target letters (all other than 'X'). Raw scores were converted to z-scores (M=0, SD=+/-1). Higher scores indicate greater inattentiveness.
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Vyvanse	Placebo
Arm/Group Description	Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks. Lisdexamfetamine: Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.	Placebo capsule, 20-70 mg, each morning for 6 weeks. Placebo: Placebo capsule, 20-70 mg, each morning for 6 weeks.
Measure Participants	16	17
Mean (Standard Deviation) [Z score]	0.63 (1.71)	1.33 (1.68)

4. Primary Outcome

Title	Assessing Physical Symptoms in Children Using Vyvanse Versus Placebo by Measuring Anxiety on the Revised Child Manifest Anxiety Scale (RCMAS)
Description	RCMAS is a self-report, 37-item questionnaire in which children agree (yes = 1) or disagree (no =0) to statements about themselves. A Total Anxiety score is computed based on 28 items, which are divided into 3 anxiety subscales: physiological anxiety (10 items), worry/oversensitivity (11 items), and social concerns/concentration (7 items). The remaining nine items on the RCMAS constitute the Lie (social desirability) subscale. The lowest scale score is 0 and the highest is 37. Raw scores were converted to z-scores (M=0, SD=+/-1). Because scores are derived from affirmative responses, a high score indicates a high level of anxiety or lie on that subscale.
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Vyvanse	Placebo
Arm/Group Description	Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks. Lisdexamfetamine: Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.	Placebo capsule, 20-70 mg, each morning for 6 weeks. Placebo: Placebo capsule, 20-70 mg, each morning for 6 weeks.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	0.12 (0.79)	-0.23 (0.95)

5. Primary Outcome

Title	Assessing Total Symptoms in Children Using Vyvanse Versus Placebo by Measuring Anxiety on the Revised Child Manifest Anxiety Scale (RCMAS)
Description	RCMAS is a self-report, 37-item questionnaire in which children agree (yes = 1) or disagree (no =0) to statements about themselves. A Total Anxiety score is computed based on 28 items, which are divided into 3 anxiety subscales: physiological anxiety (10 items), worry/oversensitivity (11 items), and social concerns/concentration (7 items). The remaining nine items on the RCMAS constitute the Lie (social desirability) subscale. The lowest scale score is 0 and the highest is 37. Raw scores were converted to z-scores (M=0, SD=+/-1). Because scores are derived from affirmative responses, a high score indicates a high level of anxiety or lie on that subscale.
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Vyvanse	Placebo
Arm/Group Description	Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks. Lisdexamfetamine: Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.	Placebo capsule, 20-70 mg, each morning for 6 weeks. Placebo: Placebo capsule, 20-70 mg, each morning for 6 weeks.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	-0.3 (0.85)	-0.56 (0.89)

6. Primary Outcome

Title	Assessing Attention Problems in Children Using Vyvanse Versus Placebo by Measuring Symptoms on the Child Behavior Checklist (CBCL)
Description	The Child Behavior Checklist (CBCL) is a widely used caregiver report form identifying problem behavior in children. The patient is rated on 113 items scored on a 3-point Likert scale (0=not true; 1=somewhat/sometimes true; 2=very true/often true). CBCL consists of eight empirically-based syndrome subscales. The range of subscale scores (summed) are: Aggressive Behavior (0-36), Anxious/Depressed (0-26), Attention Problems (0-20), Rule-Breaking Behavior (0-34), Somatic Complaints (0-22), Social Problems (0-22), Thought Problems (0-30), and Withdrawn/Depressed (0-16). Raw scores were converted to z-scores (M=0, SD=+/-1). Higher scores indicate more severe symptoms.
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Vyvanse	Placebo
Arm/Group Description	Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks. Lisdexamfetamine: Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.	Placebo capsule, 20-70 mg, each morning for 6 weeks. Placebo: Placebo capsule, 20-70 mg, each morning for 6 weeks.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	0.88 (0.69)	1.37 (0.93)

7. Primary Outcome

Title	Assessing Anxiety-Depression Problems in Children Using Vyvanse Versus Placebo by Measuring Symptoms on the Child Behavior Checklist (CBCL)
Description	The Child Behavior Checklist (CBCL) is a widely used caregiver report form identifying problem behavior in children. The patient is rated on 113 items scored on a 3-point Likert scale (0=not true; 1=somewhat/sometimes true; 2=very true/often true). CBCL consists of eight empirically-based syndrome subscales. The range of subscale scores (summed) are: Aggressive Behavior (0-36), Anxious/Depressed (0-26), Attention Problems (0-20), Rule-Breaking Behavior (0-34), Somatic Complaints (0-22), Social Problems (0-22), Thought Problems (0-30), and Withdrawn/Depressed (0-16). Raw scores were converted to z-scores (M=0, SD=+/-1). Higher scores indicate more severe symptoms.
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Vyvanse	Placebo
Arm/Group Description	Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks. Lisdexamfetamine: Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.	Placebo capsule, 20-70 mg, each morning for 6 weeks. Placebo: Placebo capsule, 20-70 mg, each morning for 6 weeks.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	0.44 (0.52)	0.76 (0.66)

8. Primary Outcome

Title	Assessing Inhibitory Control in Children When Using Vyvanse Versus Placebo Utilizing the Inhibit Subscale on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS
Description	The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Inhibit was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Lisdexamfetamine (Vyvanse)	Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.	Participants who received Placebo capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	-0.05 (1.05)	0.42 (1.16)

9. Primary Outcome

Title	Assessing Ability to Tolerate Change in Children When Using Vyvanse Versus Placebo by Utilizing the Shift Subscale on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS
Description	The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Shift was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Lisdexamfetamine (Vyvanse)	Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.	Participants who received Placebo capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	0.33 (1.22)	1 (1.44)

10. Primary Outcome

Title	Assessing Ability to Begin Tasks in Children When Using Vyvanse Versus Placebo by Utilizing the Initiate Subscale on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS
Description	The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Initiate was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Lisdexamfetamine (Vyvanse)	Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.	Participants who received Placebo capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	0.64 (0.89)	1.23 (1.04)

11. Primary Outcome

Title	Assessing Representational Memory in Children When Using Vyvanse Versus Placebo by Utilizing the Working Memory Subscale on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS
Description	The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Working Memory was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Lisdexamfetamine (Vyvanse)	Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.	Participants who received Placebo capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	0.96 (1.25)	1.69 (1.26)

12. Primary Outcome

Title	Assessing Task-oriented Monitoring in Children When Using Vyvanse Versus Placebo by Utilizing the Monitor Subscale on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS
Description	The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Monitor was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Lisdexamfetamine (Vyvanse)	Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.	Participants who received Placebo capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	0.34 (0.89)	0.84 (1.19)

13. Primary Outcome

Title	Assessing Behavior Regulation in Children When Using Vyvanse Versus Placebo by Measuring the Behavior Regulation Index (BRI) on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS
Description	The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Behavior Regulation was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

All participants who received at least one dose of each intervention were included in the efficacy analysis.

Arm/Group Title	Lisdexamfetamine (Vyvanse)	Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.	Participants who received Placebo capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	-0.04 (1.12)	0.48 (1.21)

14. Primary Outcome

Title	Assessing Cognitive Regulation in Children When Using Vyvanse Versus Placebo by Measuring the Cognitive Regulation Index (CRI) on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS
Description	The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Cognitive Regulation was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Lisdexamfetamine (Vyvanse)	Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.	Participants who received Placebo capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	0.68 (1.02)	1.33 (1.31)

15. Primary Outcome

Title	Assessing Emotion Regulation in Children When Using Vyvanse Versus Placebo by Measuring the Emotion Regulation Index (ERI) on the Behavior Rating Inventory of Executive Function (BRIEF) - PARENTS
Description	The BRIEF Parent Questionnaire is a validated 86-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Initiate, Working Memory, Plan/Organize, Organization of Materials, Monitor, Inhibit, Shift, Emotional Control). For each item, parents rate whether the child engages in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 86 (better performance) and the highest is 258 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). Emotion regulation was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Lisdexamfetamine (Vyvanse)	Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.	Participants who received Placebo capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	0.35 (1.16)	0.94 (1.39)

16. Primary Outcome

Title	Assessing Hyperactivity in Children When Using Vyvanse Versus Placebo by Administering the Conners-3 Parent Form
Description	The Conners-3 Parent Form is used to obtain the parent's observations about behavior in their child aged 6 to 18 years old. Parents rate the child's behavior on 45 items as not true at all (0) to very much true (3). The lowest scale score is 0 (better behavior) and the highest is 135 (worse behavior). The Conners 3-P includes content Scales of Inattention, Hyperactivity/Impulsivity, Learning Problems, Executive Functioning, Aggression, and Peer/Family Relations. Hyperactivity was reported as the Primary Outcome. All scores were converted to z-scores (M=0, SD=+/-1).
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Lisdexamfetamine (Vyvanse)	Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.	Participants who received Placebo capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	0.075 (1.45)	0.71 (1.56)

17. Primary Outcome

Title	Assessing Executive Functioning in Children When Using Vyvanse Versus Placebo by Administering the Conners-3 Parent Form
Description	The Conners-3 Parent Form is used to obtain the parent's observations about behavior in their child aged 6 to 18 years old. Parents rate the child's behavior on 45 items as not true at all (0) to very much true (3). The lowest scale score is 0 (better behavior) and the highest is 135 (worse behavior). The Conners 3-P includes content Scales of Inattention, Hyperactivity/Impulsivity, Learning Problems, Executive Functioning, Aggression, and Peer/Family Relations. Executive Functioning was reported as the Primary Outcome. All scores were converted to z-scores (M=0, SD=+/-1).Higher T-scores
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Lisdexamfetamine (Vyvanse)	Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.	Participants who received Placebo capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	0.97 (1.24)	1.79 (1.58)

18. Secondary Outcome

Title	Assessing Executive Functioning in Children When Using Vyvanse Versus Placebo by Administering the Behavior Rating Inventory of Executive Function (BRIEF) - CHILD SELF REPORT
Description	The BRIEF Self-Report Version assesses an adolescent's (ages 11-18) view of his or her cognitive, emotional, and behavioral functions. It is a validated 55-item questionnaire composed of 8 clinical scales that measure different aspects of executive functioning (Inhibit, Shift, Emotional Control, Monitor, Working Memory, Plan/Organize, Organization of Materials, and Task Completion). For each item, the child rates whether they engage in the behavior "never" (=1), "sometimes" (=2), or "often" (=3). The lowest scale score is 55 (better performance) and the highest is 165 (worse performance). The clinical scales form two broader Indexes (Behavioral Regulation and Metacognition) and an overall score, the Global Executive Composite (GEC). GEC was reported as the Primary Outcome. Raw scores were converted to z-scores (M=0, SD=+/-1).
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Lisdexamfetamine (Vyvanse)	Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.	Participants who received Placebo capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	0.66 (1.08)	0.59 (1.14)

19. Secondary Outcome

Title	Assessing Working Memory and Concentration in Children Using Vyvanse Versus Placebo by Measuring Performance on the Digit Span Subtest of the Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V)
Description	Digit Span repeats strings of digits of increasing length said by the examiner. Participants were asked to repeat the digits in the same sequence, either forwards or backwards. Every item on Digit Span consists of two trials. One point was awarded if the participant passed only 1 trial of a sequence length. Zero points were given if the participant failed both trials. It measures working memory and concentration with a range of scaled scores from 0-19. Raw scores were converted to z-scores (M=0, SD=+/-1). Higher scores indicate better recall and attention.
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

1 participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Lisdexamfetamine (Vyvanse)	Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.	Participants who received Placebo capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	-0.27 (0.84)	-0.29 (1.01)

20. Secondary Outcome

Title	Assessing Sustained Attention and Response Inhibition in Children Using Vyvanse Versus Placebo by Measuring Reaction Time (RT) Standard Error (SE) on the Conners Continuous Performance Task (CPT-II).
Description	Conner's Continuous Performance Task (CPT-II) measure sustained attention and response inhibition. During the CPT-II, letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). Raw scores were converted to z-scores (M=0, SD=+/-1). Hit Reaction Time (RT) Standard Error (SE) measures response speed consistency. The higher the Overall Standard Error, the greater the inconsistency in the response speed, indicating a greater amount of inattention.
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

Missing data from 2 participants in the Placebo arm and 2 participants in the Vyvanse arm

Arm/Group Title	Vyvanse	Placebo
Arm/Group Description	Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks. Lisdexamfetamine: Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.	Placebo capsule, 20-70 mg, each morning for 6 weeks. Placebo: Placebo capsule, 20-70 mg, each morning for 6 weeks.
Measure Participants	14	15
Mean (Standard Deviation) [Z-score]	0.14 (1.28)	0.57 (1.53)

21. Secondary Outcome

Title	Assessing Sustained Attention and Response Inhibition in Children Using Vyvanse Versus Placebo by Measuring RT Inter-Stimulus Interval (ISI) on the Conners Continuous Performance Task (CPT-II).
Description	Conner's Continuous Performance Task (CPT-II) measure sustained attention and response inhibition. During the CPT-II, letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). CPT-II Hit Reaction Time (RT) Inter-Stimulus Interval (ISI) Change assesses the ability to adapt to changing inter-stimulus intervals. Inter-stimulus intervals refers to the amount of time between presentation of stimuli. High t-scores indicate that RT increased as the ISI increased; negative values indicate that RT decreased as the ISI increased. Less Hit RT ISI Change indicates less variability in RT depending on the speed of presentation.
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

This assessment was not administered.

Arm/Group Title	Vyvanse	Placebo
Arm/Group Description	Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks. Lisdexamfetamine: Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.	Placebo capsule, 20-70 mg, each morning for 6 weeks. Placebo: Placebo capsule, 20-70 mg, each morning for 6 weeks.
Measure Participants	0	0

22. Secondary Outcome

Title	Assessing Sustained Attention and Response Inhibition in Children Using Vyvanse Versus Placebo by Measuring Hit Reaction Time (RT) Block Change on the Conners Continuous Performance Task (CPT-II).
Description	Conner's Continuous Performance Task (CPT-II) measures sustained attention and response inhibition. During the CPT-II, letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). Raw scores were converted to z-scores (M=0, SD=+/-1). Overall hit reaction time is the average speed of correct responses for the entire test. Lower values indicate that responses got quicker as the test progressed. High values indicate a substantial slowing in reaction times.
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

1 participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Vyvanse	Placebo
Arm/Group Description	Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks. Lisdexamfetamine: Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.	Placebo capsule, 20-70 mg, each morning for 6 weeks. Placebo: Placebo capsule, 20-70 mg, each morning for 6 weeks.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	0.75 (1.49)	1.19 (1.39)

23. Secondary Outcome

Title	Assessing Sustained Attention and Response Inhibition in Children Using Vyvanse Versus Placebo by Measuring Perseverations on the Conners Continuous Performance Task (CPT-II).
Description	Conner's Continuous Performance Task (CPT-II) measures sustained attention and response inhibition. During the CPT-II, letters were presented serially on a screen in a random order. All letters were considered target stimuli, except for the letter 'X' which is a non-target stimulus. Participants responded to target stimuli by pressing the space bar of a computer keyboard (90% of the stimuli) while withholding responses to non-target stimuli (10% of the test). CPT-II Perseverations represent responses in which reaction time was less than 100 ms; these responses are assumed to be anticipatory, random, or slow/inattentive (i.e., carried over from the previous response) because it is physiologically impossible to respond accurately in so short a time. Raw scores were converted to z-scores (M=0, SD=+/-1) to have them on a uniform metric. Higher scores indicate greater inattentiveness.
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

One participant completed the placebo arm, but dropped out of Vyvanse arm due to adverse event

Arm/Group Title	Lisdexamfetamine (Vyvanse)	Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.	Participants who received Placebo capsule, 20-70 mg, each morning in either the or last 6 weeks of the study.
Measure Participants	16	17
Mean (Standard Deviation) [Z-score]	1.02 (1.89)	0.86 (1.69)

Adverse Events

Time Frame	12 weeks
Arm/Group Title	Lisdexamfetamine (Vyvanse)		Placebo
Arm/Group Description	Participants who received Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning in either the first or last 6 weeks of the study.		Participants who received Placebo capsule, 20-70 mg, each morning in either the first or last 6 weeks of the study.
All Cause Mortality
	Lisdexamfetamine (Vyvanse)		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/17 (0%)		0/17 (0%)
Serious Adverse Events
	Lisdexamfetamine (Vyvanse)		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/17 (0%)		0/17 (0%)
Other (Not Including Serious) Adverse Events
	Lisdexamfetamine (Vyvanse)		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	1/17 (5.9%)		0/17 (0%)
General disorders
Anxiety	1/17 (5.9%)	1	0/17 (0%)	0

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.